HC Wainwright reaffirmed their buy rating on shares of Bio-Path (NASDAQ:BPTH) in a research report released on Monday morning, Stock Target Advisor reports. HC Wainwright currently has a $28.00 price objective on the stock.
Separately, ValuEngine cut Bio-Path from a hold rating to a sell rating in a research note on Friday, October 25th.
NASDAQ BPTH traded down $0.09 on Monday, hitting $9.88. The company’s stock had a trading volume of 497 shares, compared to its average volume of 65,245. Bio-Path has a 52-week low of $1.61 and a 52-week high of $73.52. The company has a current ratio of 13.85, a quick ratio of 13.85 and a debt-to-equity ratio of 0.02. The company’s 50-day simple moving average is $10.66 and its 200 day simple moving average is $12.65. The firm has a market cap of $30.75 million, a P/E ratio of -0.69 and a beta of 3.14.
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Read More: Understanding Options Trading
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.